Get the Stockscreener App
30.95
0.78%
0.24
After Hours:
30.95
Collegium Pharmaceutical Inc Stock (COLL) Latest News
Piper Sandler Has Lowered Expectations for Collegium Pharmaceutical (NASDAQ:COLL) Stock Price - Defense World
Collegium Pharmaceutical expands board, appoints new director - MSN
Collegium Pharmaceutical, Inc. Appoints Nancy S. Lurker to Its Board of Directors -February 05, 2025 at 08:00 am EST - Marketscreener.com
Collegium Pharmaceutical expands board, appoints new director By Investing.com - Investing.com South Africa
Collegium Pharmaceutical expands board with new director - Investing.com India
Collegium Pharmaceutical Expands Board with Nancy Lurker - TipRanks
Collegium Appoints Nancy S. Lurker to its Board of Directors - GlobeNewswire
Pharma Veteran Nancy Lurker Joins Collegium Board: Ex-Novartis CMO Brings M&A Expertise - StockTitan
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Collegium Pharmaceutical Insiders Sell US$2.3m Of Stock, Possibly Signalling Caution - Simply Wall St
Piper Sandler Cuts Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $36.00 - MarketBeat
SG Americas Securities LLC Sells 4,586 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Collegium Pharmaceutical, Inc. announces an Equity Buyback for $100 million worth of its shares. - Marketscreener.com
Pacer Advisors Inc. Trims Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Nisa Investment Advisors LLC Has $71,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Amid more drug-price scrutiny, biopharma companies largely keep their January hikes in check - FiercePharma
Assenagon Asset Management S.A. Trims Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Assenagon Asset Management S.A. Has $4.31 Million Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Ritholtz Wealth Management Has $968,000 Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Needham Upgrades Collegium Pharmaceutical (COLL) - MSN
Burney Co. Sells 38,157 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $43.80 - Defense World
Collegium pharmaceutical EVP Shirley Kuhlmann sells $908,627 in stock By Investing.com - Investing.com Australia
Insider Selling: Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Sells 27,500 Shares of Stock - MarketBeat
Despite the downward trend in earnings at Collegium Pharmaceutical (NASDAQ:COLL) the stock swells 18%, bringing three-year gains to 82% - Simply Wall St
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
JPMorgan Chase & Co. Has $10.71 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
JPMorgan Chase & Co. Grows Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Raised to “Buy” at Needham & Company LLC - Defense World
Collegium Pharmaceutical (NASDAQ:COLL) Earns Buy Rating from HC Wainwright - Defense World
Collegium Pharma spikes after 2025 outlook - MSN
Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Upgraded by Needham & Company LLC - MarketBeat
Collegium Pharmaceutical Unveils 2025 Financial Projections - Yahoo Finance
COLLCollegium Pharmaceutical, Inc. Latest Stock News & Market Updates - StockTitan
Collegium Pharmaceutical (NASDAQ:COLL) Trading 2.8% HigherShould You Buy? - MarketBeat
Collegium Pharma stock spikes on 2025 outlook (COLL:NASDAQ) - Seeking Alpha
Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2025 -January 08, 2025 at 08:00 am EST - Marketscreener.com
Collegium Provides 2025 Financial Guidance and Business Update - GlobeNewswire
Collegium Pharmaceutical Projects Record $750M Revenue in 2025, ADHD Drug Leads Growth - StockTitan
Collegium Pharmaceutical (NASDAQ:COLL) Sets New 12-Month LowHere's What Happened - MarketBeat
Collegium stock hits 52-week low at $28.46 amid market challenges - Investing.com Australia
Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards? - MSN
Collegium Pharmaceutical (NASDAQ:COLL) Hits New 12-Month LowWhat's Next? - MarketBeat
Franklin Resources Inc. Has $1.16 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Geode Capital Management LLC Has $29.97 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Pulling back 6.0% this week, Collegium Pharmaceutical's NASDAQ:COLL) three-year decline in earnings may be coming into investors focus - Yahoo Finance
Sanctuary Advisors LLC Buys 1,731 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Purchased by Barclays PLC - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Barclays PLC - Defense World
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):